BRIEF-Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209

Oct 23 (Reuters) - Zymeworks Inc. ZYME.O:

• ZYMEWORKS: ENTERS EXCLUSIVE GLOBAL LICENSE & COLLABORATION AGREEMENT WITH ROCHE FOR ZW209, A TRISPECIFIC T CELL ENGAGER TARGETING DLL3

• ZYMEWORKS: TO GET $55 MILLION UPFRONT PAYMENT & $40 MILLION PAYMENT UPON INITIATION OF PHASE 1B TRIAL

• ZYMEWORKS: POTENTIAL TO GET UP TO $718 MILLION IN ADDITIONAL DEVELOPMENT, COMMERCIAL & SALES-BASED MILESTONES UNDER ROCHE DEAL

• ZYMEWORKS: ELIGIBLE TO GET TIERED HIGH-SINGLE-DIGIT TO MID-TEEN ROYALTIES ON GLOBAL NET SALES PROTECTED BY PATENTS EXTENDING INTO 2040S

• ZYMEWORKS: ROCHE TO FUND PHASE 1A TRIAL & HAVE EXCLUSIVE RIGHT TO DEVELOP & COMMERCIALIZE ZW209 GLOBALLY

Further company coverage: ZYME.O